ORIJINAL ARAȘTIRMA ORIGINAL RESEARCH

DOI: 10.5336/pediatr.2020-78942

# The Effect of Probiotics Added to Maternal Nutrition on Infantile Colic: A Systematic Review and Meta-analysis

Maternal Beslenmeye Eklenen Probiyotiklerin İnfantil Kolik Üzerine Etkisi: Sistematik Bir İnceleme ve Meta-analiz

<sup>®</sup>Aysu YILDIZ KARAAHMETª, <sup>®</sup>Gülümser DOLGUN<sup>♭</sup>, <sup>®</sup>Metehan ÖZEN<sup>◦</sup>

<sup>a</sup>Department of Midwifery, Haliç University Faculty of Health Sciences, İstanbul, TURKEY <sup>b</sup>Department of Midwifery, İstanbul University Faculty of Health Science İstanbul, TURKEY <sup>c</sup>Acıbadem University Faculty of Medicine, Department of Child Health and Diseases, İstanbul, TURKEY

ABSTRACT Objective: This study thoroughly evaluates the available evidence examining the effect of probiotics and derivatives added to maternal nutrition on infantile colic. Material and Methods: A comprehensive, systematic search of PubMed, Web of Science, the Cochrane Library, CINAHL and ULAKBIM databases was completed. In the systematic review, we examined the evidence about probiotics that could potentially be included. Contrary to what is usual, our review included maternal nutrition, but not infant feeding. Outcomes data including treatment success and crying times of infantile colic were collected to conduct an analysis. Meta-analysis of study outcomes was performed using Review Manager. The Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) approach was used to assess the quality of the body of evidence for each outcome of this meta-analysis. PROSPERO; registration number CRD42020155237. Results: In the review, 4 studies (1,110 participants) were included. The agreement between the 2 researchers was excellent, with Cohen kappa scores [95% confidence interval (CI)]=0.95 (I0.88-1) for article selection and 0.97 (I0.92-1) for bias scoring. The end of the intervention did not find a significant difference in treatment success between the 2 groups [risk ratio (RR) 1.14; 95% CI (0.4, 2.71)]. In a sensitivity analysis using the fixed effect model, we found a significant difference in favor of probiotics [RR 0.92; 95% CI (0.60, 1.42)]. Conclusion: Research suggests that the addition of some probiotics in the diet of mothers is reasonable for the treatment of infantile colic. However, more research is needed.

Keywords: Probiotic; prebiotic; infantile colic; maternal nutrition; meta-analysis ÖZET Amac: Bu çalışma, anne beslenmesine eklenen probiyotik ve türevlerinin, infantil kolik üzerindeki etkisini inceleyen mevcut kanıtları derinlemesine değerlendirmektedir. Gereç ve Yöntemler: PubMed, Web of Science, Cochrane Library, CINAHL ve ULAKBİM veri tabanlarının kapsamlı ve sistematik arastırması tamamlandı. İnfantil kolik tedavi başarısı ve ağlama sürelerini içeren sonuç verileri, analiz yapmak için toplandı. Sistematik incelemede, potansiyel olarak dâhil edilebilecek probiyotiklerle ilgili kanıtları inceledik. Alışılmışın aksine incelememiz, bebek beslemesini değil anne beslenmesini içeriyordu. Çalışma sonuçlarının metaanalizi, "Review Manager" kullanılarak gerçekleştirildi. Tavsiye, Değerlendirme, Geliştirme ve Değerlendirme Çalışma Grubu Dereceleri (GRADE) yaklaşımı, bu metaanalizin her bir sonucunun kanıt kalitesini değerlendirmek için kullanıldı. PROSPERO; kayıt numarası CRD42020155237 idi. Bulgular: İncelemeye, 4 çalışma (1.110 katılımcı) dâhil edildi. Makale seçimi için Cohen kappa skorları [%95 güven aralığı (GA)]=0,95 (I0,88-1) ve ön vargı skorlaması icin 0,97 (I0,92-1) ile 2 arastırmacı arasındaki uyum mükemmeldi. Müdahalenin sonunda 2 grup arasında tedavi basarısında anlamlı bir fark bulamadık [risk oranı (RO) 1.14: %95 GA (0,4; 2,71)]. Sabit etki modelini kullanan bir duyarlılık analizinde, probiyotikler lehine anlamlı bir fark bulduk [RO 0,92; %95 GA (0,60; 1,42)]. Sonuc: Araştırmalar, annelerin diyetine bazı probiyotiklerin eklenmesinin, infantil kolik tedavisi için makul olduğunu göstermektedir. Ancak daha fazla araştırmaya ihtiyaç vardır.

Anahtar Kelimeler: Probiyotik; prebiyotik; infantil kolik; maternal beslenme; meta-analiz

Infantile colic is defined on Wessel's criteria, also known as the 'rule of threes', which as paroxysms of irritability, fussing or crying lasting  $\geq$ 3 hours

per day on  $\geq 3$  days per week for >3 weeks".<sup>1</sup> Infantile colic is now a prevalent issue that one in five babies (20%) less than three months old has been facing.<sup>2</sup>

Correspondence: Aysu YILDIZ KARAAHMET Department of Midwifery, Haliç University Faculty of Health Sciences, İstanbul, TURKEY/TÜRKİYE E-mail: aysuyildizz@hotmail.com Peer review under responsibility of Turkiye Klinikleri Journal of Pediatrics. Received: 13 Sep 2020 Received in revised form: 08 Jan 2021 Accepted: 03 Feb 2021 Available online: 03 Mar 2021 2146-8990 / Copyright © 2021 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Although infantile colic is considered a self-limiting and benign problem, it is a stressful problem for both newborns and parents.<sup>3-5</sup> Infantile colic may cause health problems in the short and long term for newborns, it is also associated with poor quality of life for parents and negatively affects the social and psychological state.<sup>6,7</sup>

There is no clear line regarding infantile colic etiology. However, it is thought that there may be the mode of delivery, the feeding style of the newborn, birth weight, lactose intolerance, intestinal contractions, gas food hypersensitivity, parental misinterpretation of the normal crying model, or various combinations of these.<sup>3,8,9</sup> Efficiency of applying manipulative therapies, probiotics, dietary modification, complementary and alternative therapies (herbal formulations, sucrose or glucose) and pain-relieving agents have been heretofore analyzed and evaluated.<sup>10,11</sup> Recent research and related evidence suggest that motility impairment and intestinal neuronal hyperexcitability are the most important pathogenic factor in infantile colic etiology.<sup>12-15</sup> There is growing evidence that intestinal microbiota differs from healthy controls in infants with colic. It is also evident that a large number of aerobic bacteria e.g. Helicobacter pylori was detected in the microbiota of infants having colicky symptoms such as excessive crying or irritability, nonetheless, microbiota of infants who are not diagnosed as colic are more diverse than the former.

Use of probiotics and prebiotics in alleviating and curing colic symptoms as well as other related problems e.g. functional intestinal disorders has been searched in numerous studies in order to make accurate conclusions.<sup>16,17</sup> Microbiota is believed to be changed or modified by some factors and this alteration in microbiota may trigger the colic suffering in babies. Hence, prophylactic use of probiotics may relieve the colic pain by ensuring the balance of microbial bowel colonization. However, it should not be forgotten that the colic does not have a single reason, its etiology is multifactorial and although many treatments are available for infantile colic, there is no universally effective and acceptable treatment.<sup>18</sup> Hence, additional approaches to treatment can be valuable. Probiotics are an increasingly popular treatment intervention that is particularly popular with infantile colic therapy.<sup>19,20</sup> Numerous studies have shown that the use of probiotics in the treatment of infantile colic is promising and there is evidence for the efficacy of probiotics in infant feeding for infantile colic.<sup>21-23</sup> However, there is a lack of evidence for the efficacy of probiotics added to maternal nutrition, and there is no guidance available to clinicians or the community.<sup>24</sup> Therefore, it is important to evaluate whether probiotics added to maternal nutrition are effective as primary or preventive treatment for newborn colic.<sup>25</sup>

The aim of this study is to figure out the efficiency and safety of pro-prebiotics added to maternal nutrition in preventing or reducing severity of infantile colic.

## MATERIAL AND METHODS

Systematic review and meta-analysis of studies determining the effect of safety of probiotics, prebiotics or synbiotics (PPS) added to the diet of mothers on infantile colic were performed. The study was prepared in accordance with the recommendations in the "Systematic Reviews Handbook of Cochrane Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-analysis".

#### SEARCH STRATEGY

The systematic literature review of this study was registered with the "International Prospective Register of Systematic Reviews (PROSPERO; registration number CRD42020155237)." A comprehensive, systematic search of PubMed, Web of Science, the Cochrane Library, CINAHL, ULAKBİM databases was completed from the earliest date available until January 2020. The main key word and MESH headings used in this study are as follows: '(Colic or infantile colic or excessive crying) and (probiotics or prebiotics or synbiotics) and (pregnancy or postpartum) and (maternal nutrition or maternal diet). The search strategy was modified according to the specifications of each database. Moreover, the reference lists of retrieved articles were reviewed to identify further undiscovered relevant articles. The detailed information is shown in Figure 1.




FIGURE 1: Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) diagram.

#### INCLUSION AND EXCLUSION CRITERIA

Studies were included if they met the following criteria: (1) Observational study designs (cohort, casecontrol, cross-sectional) and randomized controlled trials (RCTs), (2) Studies published only in English and Turkish languages were included, (3) Prophylactic, PPS (any dose or composition) added to the mother's diet during pregnancy or postpartum period, (4) Healthy pregnant women over 36 weeks of gestation in studies, (5) Mothers who breastfeed their baby predominantly -more than 50% of baby's daily diet.

Studies were excluded in the light of the following criteria: (1) Those who use PPSs before the thirtysixth gestational week, (2) Receive alternative therapies (massage, nutritional diets, etc.) other than PPSs for colic treatment, (3) Babies who are fed with formula only or more than 50% of their daily diet, (4) Preterm or low birth weight babies, (5) Mothers who used antibiotics during pregnancy or postpartum period were not included in the review.

### STUDY SELECTION AND DATA EXTRACTION

After the duplicate articles retrieved from the different databases were removed, 2 independent investigators (A.Y.K., G.D.) screened titles and abstracts to identify which studies met the inclusion and exclusion criteria. Studies that were fulfilled by the inclusion criteria or those with eligibility that could not be identified from the title/abstract screening were retrieved for full-text and review by 2 investigators (A.Y.K., G.D.). Disagreements between reviewers were resolved by consulting with a third reviewer (M.Ö.) who was blind to other reviewers' decisions on inclusion.

Two investigators independently extracted the following data: Characteristics of participants, interventions and controls, methods, outcomes. When the data of the articles were insufficient or uncertain, one of the authors (A.Y.K.) contacted the first author to request detailed information about the research via email. The quality of the selected articles was assessed by The Effective Public Health Practice Project (EPHPP) checklist, which is a quality assessment tool for quantitative studies.

#### ASSESSMENT OF RISK OF BIAS

Two investigators (A.Y.K. and G.D.) independently assessed the study for risk of bias, using the criteria recommended in the Cochrane Handbook for Systematic Reviews of Interventions: sequence generation; allocation concealment; blinding of parents and health professionals; blinding of outcome assessment; incomplete outcome data; selective outcome reporting and other potential threats to validity. We judged each domain as being at low, high or unclear risk of bias. We compared the judgements and discussed and resolved any inconsistencies in the assessments. A third investigator (M.Ö.) made a final decision if consensus was not reached by the first two investigators.

#### QUANTITATIVE DATA SYNTHESIS AND ANALYSIS

Outcomes data including treatment success and crying times of infantile colic were collected to do an analysis. Meta-analysis of study outcomes was performed using RevMan 5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark). The Grades of Recommendation, Assessment, Development and Evaluation Working Group (GRADE) approach was used to assess the quality of the body of evidence for each outcome of this meta-analysis. The quality of evidence was initially considered "High" and could be downgraded based on the following 5 factors: 1) limitation of design, 2) indirectness of evidence, 3) inconsistency of results, 4) imprecision of results, and 5) high probability of publication bias.

Pooled values were calculated as the inverse variance-weighted mean of the logarithm of risk ratio (RR) with 95% confidence intervals (CI) to assess the strength of association between probiotics and treatment success. For analysis of continuous data, mean differences (MD) or standardized MD with 95% CI were used. If all studies report the outcome, using the same scale such as Barr Baby Diary Scale for treatment success MD was used. The follow-up time of the included studies differs from 7 days 30 to 1 year. In this meta-analysis, all of them were accepted.

The random-effects model was used to account for variability between studies and its effect on the intervention. The I<sup>2</sup> statistic was used to measure the heterogeneity between included studies and the I<sup>2</sup> value of 25% which indicates a small, 50% a moderate, and 75% a high degree of heterogeneity. Coherence between researchers for independent article selection and bias scores was evaluated using the Cohen kappa statistic. Effect size was excepted 0.2 as small, 0.5 as moderate, and 0.8 as large using Cohen's criteria for pooled estimates.


# RESULTS

The electronic database search and hand-search yielded 147 potentially relevant studies. After removing duplicates, we screened 89 articles based on title or abstract. The remaining 17 full texts were assessed for the eligibility. For the full-text screening, a third reviewer was needed to resolve disagreements for blinding of the studies. Four trials met all eligibility criteria and were included in qualitative synthesis (Figure 1). Only 50% (n=2) of the studies graded 1 according to EPHPP tool.<sup>24</sup> Coherence between the observers was excellent both in the selection of articles and in the scoring of selected articles in terms of bias Cohen kappa (95% CI)=0.95 (I0.88-1) for article selection, 0.97 (I0.92-1) for bias scoring.

The quality of evidence included in this metaanalysis was assessed using the GRADE approach. Treatment success and crying times were the outcomes assessed. The results regarding the outcomes showed low to moderate evidence. The GRADE analysis can be seen on Table 1.

# THE CHARACTERISTICS OF INCLUDED STUDIES AND POPULATION

Three RCTs and a single interventional study, including 1,036 mothers and babies, were included in our systematic review and 3 RCTs were included in the meta-analysis.<sup>26-29</sup> The characteristics of the studies are summarized in Table 2. With one exception, all trials are double-blind and placebo-controlled.<sup>28</sup> All articles included in the study were published in English. All of the mothers included in the study reported that they breastfed their babies (>50%). In a single study, its design started in the prenatal period (36th gestational week) by adding probiotics and continued until the first month after birth.<sup>27</sup> In a single RCT prenatal period (36th gestational week) was started by adding synbiotics to mother feeding and continued until the first month after delivery.<sup>26</sup> In newborns diagnosed with postpartum colic in a single interventional and a single RCT made by Iacovou, it started to work by adding a prebiotic diet to the mother diet and continued for 7-10 days.<sup>28,29</sup>



The duration of the interventions ranges from 10 days to six month.<sup>27,28</sup>

One study used synbiotic instead of probiotics, and prebiotic diet instead of probiotics.<sup>27-29</sup>

# THE CHARACTERISTICS OF THE ADDED INTERVENTION

Among the articles included in the study, Baldassarre et al., a probiotic preparation containing different probiotic strains (*Lactobacillus paracasei* DSM 24733, *Lactobacillus plantarum* DSM 24730, *Lactobacillus acidophilus* DSM 24735 and *Lactobacillus delbruecki*), Iacovou et al. study, a prebiotics diet-FOPMAP (Prebiotic diet-fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols) and the Kukkonen et al.'s study, a synbiotic preparation containing different probiotic strains (*Lactobacillus rhamnosus GG* and *L. rhamnosus LC705, Bifidobacterium breve Bb99*, and *Propionibacterium freudenreichii* ssp *shermanii*) were used.<sup>26-28</sup>

### CONTROL GROUP

While two studies used placebo as a control group, in a study evaluating its effectiveness against the Australian diet, a group that was diagnosed with colic in the daily diet in an interventional study was later assigned to the probiotic group and its effectiveness was evaluated (Table 2).<sup>26-29</sup>

The duration of the addition of pro-prebiotics to maternal nutrition began in 3 studies at 36 weeks of gestation and continued in the postpartum period. This period ranged from 2 to 6 months.<sup>26,27</sup> In two studies, pro-prebiotics were added to the maternal diet 7 days after the diagnosis of colic and continued to be given for 7-10 days. The dosage schedule and the way of administration of pro-probiotics varied significantly between RCTs.

In any of the studies included, no adverse side effects were reported in the mother or newborn for the supplement added to the mother's diet.

#### EFFECTS OF INTERVENTIONS

#### **Primary Outcomes**

Treatment success at the end of intervention

Except for an interventional study, three articles reported results of treatment success at the end of the intervention, and we performed random effect meta-

			TABLE 2: Characteristic	Characteristics of studies included in the systematic reviews and meta-analysis	systematic reviews	and meta-analysis.		
Eiret authore			Inclusion criteria	Intervention			Withdrawal number and	Drimary outcomae
time, country	Study design	Population	Exclusion criteria	(dose/duration of intervention)	Comparison	Follow-up time	reason	Secondary outcomes
lacovou, 2018, Australia	RCT	13 mothers	Inclusion criteria	FODMAP diet (Fermentable,	Typical Australian diet	Control after the	Intervention group (N: 1)	Primary outcomes: at the end of
		1-Prebiotic diet	-Mothers with a baby	oligosaccharides, disaccharides,		diagnosis of infantile colic	Control Group (N: 0)	each diet intervention was the
		(FODMAP diet): (N: 6)	younger than 9 weeks	monosaccharides and polyols)		(at the beginning)		change in combined infant crying
		2-Control Group	-Diagnosed as colic	The response group was given		and on the 10th day		and restlessness time (on average
		(Australian diet): (N: 7)	according to	a 10-day FODMAP diet.				8-10 days). Secondary outcomes
			Wessel criteria					include infant feeding, sleep time
			-Mothers between					and wakefulness and periods of
			the ages of 18-45 and					content, maternal health (anxiety,
			who want to change					depression and stress), and
			their diet					measured fecal and breast milk
			-Mothers who are					indices.
			breastfeeding their					
			baby only or predominantly					
			Exclusion Criteria					
			-If there is any underlying					
			medical condition or					
			mother-infant pairs					
			requiring medication					
			were excluded.					
lacovou, 2017, Australia	Interventional	18 mothers	Inclusion criteria	FODMAP diet (Fermentable,	Their diets	After diagnosis of		Primary outcomes: at the end of
			-Mothers with a baby	oligosaccharides, disaccharides,		infantile colic		each diet intervention was the
			younger than 9 weeks	monosaccharides and polyols)		(at the beginning) and		change in combined infant crying
			-Diagnosed as colic	A 7-day FODMAP diet was given.		at the end of the		and restlessness time (on average
			according to Wessel criteria			7-day diet intervention		8-10 days).Secondary outcomes
			-Mothers hetween the ares					include infant feeding sleen time
			01 18-45 and who want to					and wakefulness and periods of
			change their diet					content, maternal health (anxiety,
			-Mothers who are					depression and stress), and
			breastfeeding only or					measured fecal and breast milk
			predominantly					indices.
			-Term born and-not					
			exposed to any treatment					
			for colic (such as simethicone					
			and wind drops) or					
			anti-reflux medicine					
			Exclusion Criteria					
			-A common disease condition					
			requiring medication,					
			the current use of dietary					
			restriction in response to					
			a baby with colic, and-followed					
			the vegan diet.					

Retrotion         Montion	Motion Bill Control For Antion F			TABLI	TABLE 2: Characteristics of st	acteristics of studies included in the systematic reviews and meta-analysis (continue)	ematic reviews and m	eta-analysis <i>(continu</i>	е).	
Buy long         Evaluation (e)         Evaluation (e	Kuloni         Education         E	First authors,			Inclusion criteria	Intervention			Withdrawal number and	Primary outcomes
Eff         Control focusion         Instrumention         Control focusion         Enstimution County	Rt         Separative         Restering case	time, country	Study design	Population	Exclusion criteria	(dose/duration of intervention)	Comparison	Follow-up time	reason	Secondary outcomes
Three function         Operation of the function         Considering of the function         Considerinfor	Timento (xu)         permission         Sumetholisation         Control (xu)	Baldassarre, 2016, Italy	RCT	66 pregnant women	Inclusion criteria-Healthy,	Intervention (n=33:	Control (n=34:	Postpartum	Experiment Group (N: 0)	Primary outcomes analysis of breast
Protectical         Control endersity Exploration         Control Endersity Ex	Protein (n. s.)         Investinging classification (network)         Investing classification (network)         ting (network)         <thinvesting (networ</thinvesting </thinvesting 			1-Intervention Group 1	pregnant women with low	30 breastfeeding and	29 breastfeeding and	Day 0 and Day 30	Control Group (N: 1)	milk for cytokine patterns,
Zome (cold)         Educio (cold)         Hydrometric (cold)	Sound Source (month)         Exation Clarice on the Animative description of the month of			(Probiotic): (n: 33)	obstetric risk	3 mix feeding):	5 mixture feeding;			secretion in breast milk and feces IgA,
Place         Tensing rate and model         Instant product         Instant product         Instant product           Present price         Contract product         Contract<	Periodicitation         Control         Control         Control         Control           Prevent prevents         Control         Control         Control         Control         Control           Control         Control         Control         Control         Control         Control         Control           Control         Control         Control         Control         Control         Control         Control         Control           Control         Contro         Control         Contro			2-Control Group	Exclusion Criteria	high concentration,	1 of them could not follow):			fecal lactoferrinSecondary outcomes:
Of diadets lyperations       segment () rotads         Anomunal dispersions       different () rotads         Anomunal dispersions <td< th=""><th>Ref         Operation         Operation         Operation           Operation         Operation         Operation         Operation         Operation           Operation         Operation         Operation         Operation         Operation         Operation           Operation         Operation         Operation         Operation         Operation         Operation         Operation           Operation</th><td></td><td></td><td>(Placebo): (n: 33)</td><td>-Pre-existing clinical conditions</td><td>multi-strain probiotic</td><td>corn starch</td><td></td><td></td><td>safety, anthropometric data and</td></td<>	Ref         Operation         Operation         Operation           Operation         Operation         Operation         Operation         Operation           Operation         Operation         Operation         Operation         Operation         Operation           Operation         Operation         Operation         Operation         Operation         Operation         Operation           Operation			(Placebo): (n: 33)	-Pre-existing clinical conditions	multi-strain probiotic	corn starch			safety, anthropometric data and
Reference         Endemnitiestication (university including lange)         Endemnitiestication (university including lange)         Endemnitiestication (university including lange)           Reference viral langend (university lange)         Endemnitiestication (university lange)         Endemnitiestication (university lange)         Endemnitiestication (university lange)         Endemnitiestication (university lange)           Reference regions         Endemnitiestication (university lange) <th>Induction         Collection         Collection         Collection           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)</th> <td></td> <td></td> <td></td> <td>such as diabetes, hypertension,</td> <td>supplement, in packs.</td> <td></td> <td></td> <td></td> <td>gastrointestinal events (insufficiency,</td>	Induction         Collection         Collection         Collection           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)           Reference         (understanded exect)         (understanded exect)         (understanded exect)				such as diabetes, hypertension,	supplement, in packs.				gastrointestinal events (insufficiency,
Mature tester, tester, solution desires, vol. totalise desires, desir	Atomus design etages				diabetes; hypertension;	4 different lactobacilli strains				bowel movements and colic symptoms
entron logicity ter descent programmer, program         BV373, tabbia           er descent programmer, program         BV373, tabbia           programmer, program         BV373, statut           programer, program         BV373, statut      <	entenderio entro de la control				Autoimmune disease;	(Lactobacillus paracasei				in the newborn or toddler period
Indexervicie (coston index) (proteomic (coston index) (coston	Indefension         Indum (N) 47.01           Indefension         Indefension           Indefension				asthma; allergy; kidney or	DSM 24733, Lactobacillus				according to Rome III criteria)
Independencing regionery (integrations)         Independencing (integrations)	International (Marking Sector (Marking				liver diseases; viral, bacterial or	plantarum DSM 24730,				
Image: media: programe (arror of a constraint)         Image: media: programe (arror of a constraint)         Image: media: program (arror of a constraint)         Image: media: program (arror of a constraint)                dises and program (arror of a constraint)              dises and	Mingenetice preparities         Distribution         Distribution         Distribution           desearand pretendings         desearand prediction         desearand prediction         desearand prediction           desearand prediction         desearand prediction         desearand prediction         desearand prediction         desearand prediction           desearand prediction         desearand				protozoan infection; anemia;	Lactobacillus acidophilus				
Image: constraint of present the production of the productin production of the productin production of the producti	Image: Image:				twin pregnancies; pregnancy	DSM 24735 and Lactobacillus				
elingtination of the section of the	erder trudy protocial erder, Use of other protocial of ung the study protocial of ung the study protocial erder at 2131 and 1-Response Council (1-				disease and preterm births;	delbrueckii subsp bulgaricus				
Pertant Level of the proposition of up to the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study protocial during the study material during the study mat	Reduction during the study protocol during the				smoking more than 10 cigarettes	DSM 24734), 3 strain				
during the study protocol         and DSM 2473.           Rederate immericance         Biodobacterimine DSM 2473.           Biodobacterimine DSM 2473.         Biodobacterimine DSM 2473.           Biodobacterimine DSM 2473.         Biodobacterimine DSM 2473.           Biodobacterimine DSM 2473.         Biodobacterimine DSM 2473.           Biodobacterimine DSM 2473.         Biodobacterimine DSM 2473.           Ref         39 program vomen         Control on cyclin           Imperiod         Program vomen         Control on cyclin         Train of measurements           Cymbolo, (m-416).         Control on cyclin         Train of measurements         Network undobacterimin           Cymbolo, (m-417).         Control on cyclin         Train of measurements         Network undobacterimin           Cymbolo, (m-417).         Control on cyclin         Train of measurements         Network undobacterimin           Cymbolo, (m-417).         Control on cyclin         Train of t	Andread         Andread <t< th=""><td></td><td></td><td></td><td>per day; Use of other probiotics</td><td>bifidobacteria (Bifidobacterium</td><td></td><td></td><td></td><td></td></t<>				per day; Use of other probiotics	bifidobacteria (Bifidobacterium				
Rideaterium base DSN 2473 in the total consistency	Riddetermine DSL 2473 Biologio valle loppined base 2473 jand Statistica antipiotion (1-48; 2004) or diali (1-				during the study protocol	longum DSM 24736,				
Online value loppinad detate 3737 and detate 3737 and detate 3737 and sector 373 and 378 propertivenes         Online value loppinad detate 3737 and 389 propertivenes         Online value between 389 propertivenes         Online value 389 propertivenes <t< th=""><th>Oblige used in the proprietion         Oplige</th><td></td><td></td><td></td><td></td><td>Bifidobacterium breve DSM 24734)</td><td></td><td></td><td></td><td></td></t<>	Oblige used in the proprietion         Oplige					Bifidobacterium breve DSM 24734)				
International contraction         In	Retrai 2473) and Sreptosocus themptilis         Image Sreptosocus themptilis           RV         33 pegnent women         Image Sreptosocus themptilis         Image Sreptosocus themptilis           RV         33 pegnent women         Image Image Sreptosocus themptilis         Image Sreptosocus themptilis         Image Sreptosocus themptilis           RV         33 pegnent women         Image Image Sreptosocus themptilis         Image Sreptosocus themptilis         Image Sreptosocus themptilis         Image Sreptosocus themptilis         Image Sreptosocus Sreptosocus Sreptosocus Image Sreptosocus Sreptosocus Image Sreptosoc					900 billion viable lyophilized				
Testorocoustemonylic       Testorocoustemonylic       Testorocoustemonylic       Tentonocoustemonylic       h=""><th>Carponocoust termophile       Carponocoust termophile         RCT       839 pegrant women       Important       Not 2473 statent       Not 2473 statent         RCT       839 pegrant women       Important       Not 2473 statent       Not perced up 1339         RCT       839 pegrant women       Important       Not perced up 138       Not perced up 133         1-Response Group       Pegrant women with       Respired capstels containing       Vot perced up 133       Not perced up 133         2-Control Group       Berginant women       Respired capstels containing       Vot perced up 133       Not perced up 133         2-Control Group       Berginant women       Respired capstels containing       Vot perced up 133       Not perced up 133         2-Control Group       Berginant mixture of 36 weeks       Intervention       36, 12 and 24 months       Respired up 133         2-Control Group       Berginant mixture of 36 weeks       Intervention       36, 12 and 24 months       Percention to tholowapt and         2-Control Group       Berginant mixture of 36 weeks       Intervention       1000000000000000000000000000000000000</th><td></td><td></td><td></td><td></td><td>bacteria 24737) and</td><td></td><td></td><td></td><td></td></th<>	Carponocoust termophile       Carponocoust termophile         RCT       839 pegrant women       Important       Not 2473 statent       Not 2473 statent         RCT       839 pegrant women       Important       Not 2473 statent       Not perced up 1339         RCT       839 pegrant women       Important       Not perced up 138       Not perced up 133         1-Response Group       Pegrant women with       Respired capstels containing       Vot perced up 133       Not perced up 133         2-Control Group       Berginant women       Respired capstels containing       Vot perced up 133       Not perced up 133         2-Control Group       Berginant women       Respired capstels containing       Vot perced up 133       Not perced up 133         2-Control Group       Berginant mixture of 36 weeks       Intervention       36, 12 and 24 months       Respired up 133         2-Control Group       Berginant mixture of 36 weeks       Intervention       36, 12 and 24 months       Percention to tholowapt and         2-Control Group       Berginant mixture of 36 weeks       Intervention       1000000000000000000000000000000000000					bacteria 24737) and				
RCI     G9 gregnant voluent     Intervention (1=468):     0.8 g CGS (bovine origin)     Tring of measurements:     Net reported, U01339       RCI     93 gregnant voluent     Intervention (1=468):     0.8 g CGS (bovine origin)     Tring of measurements:     Net reported, U01339       (Synbiotic) (1=471):     (reinterventiont)     Reevied capsules containing     was given in placebo     3, 6, 12 and 24 months     Net reported, U01339       (Synbiotic) (1=471):     cinitiants     De Grand Group     apegnant maturus of 36 weeks     (reincorystalline cellubes)     3, 6, 12 and 24 months     Net reported, U01339       (Synbiotic) (1=471):     cinicas     CrOs Bifdobacterium breve     (reincorystalline cellubes)     0, 6, 12 and 24 months     25 participants       (Placebo) (1=471):     cinicas     CrOs Bifdobacterium breve     (reincorystalline cellubes)     2, 12 and 24 months     25 participants       (Placebo) (1=471):     cinicas     CrOs Bifdobacterium breve     (reincorystalline cellubes)     2, 12 and 24 months     2, 2 and 24 months       (Placebo) (1=471):     cinicas     CrOs Bifdobacterium breve     (reincorystalline cellubes)     2, 2 and 24 months     2, 2 and 24 months       (Placebo) (1=471):     cinicas     CrOs Bifdobacterium breve     (reincorystalline cellubes)     2, 2 and 24 months     2, 2 and 24 months       (Placebo) (1=471):     cinicas     CrOs Bifdobacteri	RUT     393 pregrant women     Intervention (n=48):     0.80 GGG (hovine origin)     Timing of measurements:     Not reported, but 339       RUT     339 pregrant women     Intervention (n=48):     0.8 GGG (hovine origin)     Timing of measurements:     Not reported, but 339       1-Response Group     Pregnant women with     Reevield capsules on taining     we signer in placebo     3, 6, 12 and 24 months     Pregnant womes       2-Control Group     allergies from antenatal     Lactobacillus frammosus GG and     pus sugar syrup).     3, 6, 12 and 24 months     Pregnant womes       2-Control Group     allergies from antenatal     Lactobacillus frammosus GG and     pus sugar syrup).     3, 6, 12 and 24 months     Preformati, blow-up and       2-Control Group     allergies from antenatal     Lactobacillus frammosus GG and     pus sugar syrup).     2, 2, and 24 months     Preformati, blow-up and       2-Control Group     allergies from antenatal     Lactobacillus frammosus GG and     pus sugar syrup).     2, 2, and 24 months     Preformati, blow-up and       2-Control Group     allergies from antenatal     Lactobacillus frammosus GG and     pus sugar syrup).     2, 3, 12 and 24 months     Preformati, plow-up and       2-Strand Strand     fination     Crois Biologa and Propolobacierium     presoperation     3, 6, 12 and 24 months     Preformati, plow-up and       2-Strand Strand     fination					1 Streptococcus thermophilus				
RCT         039 pegnant women         Inclusion criteria         Intervention (m-466):         0.8 g COS (bovine origin)         Timing of measurements:         Not reported: but 039           1-Response Group         -Pegnant women with         Reevied capaules containing         was given in placebio         3, 6, 12 and 24 monts         Proteinst women with           (3) brotis (m-468):         circliner at high risk of         a pegnant mixture of 36 weeks         (microcrystalline calluose)         3, 6, 12 and 24 monts         Paticipants completed           (3) brotis (m-468):         circliner at high risk of         a pegnant mixture of 36 weeks         (microcrystalline calluose)         3, 6, 12 and 24 monts         Paticipants completed           (2) control Group         allegies from antental         Ladobacillus framousus GG and         pus sugar syrup).         Paticipants         Paticipants           (Placebo) (m-471):         circline         Badobacillus framousus GG and         pus sugar syrup).         Paticipants         Paticipants           (Placebo) (m-471):         circline at high risk of         reforebacillus framousus GG and         pus sugar syrup).         Paticipants         Paticipants           (2) and 2 words         circline at high risk         Cr05, Bifidobacterium         Paticipants         Paticipants         Paticipants           (3) words sp and Pacpiolobacterium <t< th=""><th>RCT         039 program women         Industrion criteria         Intervention (1-468):         0.3 g CGS (bovine origin)         Timing of measurements:         Net reported. but 339           1-Response Group         -Pegnant women with         Reeevied capsules containing         was given in placebo         3, 6, 12 and 24 monts         Perpanst womelsed           (Synbiotic) (n=471):         children at high risk of         a pegnant mixture of 36 weeks         (microcrystaline cellubes         3, 6, 12 and 24 monts         Perpanst montsed           2-Control Group         alleges from antenatal         Ladobaceliu harmous GG and         psugar synty).         0.3, 6, 12 and 24 monts         Perpanst montsed           2-Control Group         alleges from antenatal         Ladobaceliu harmous GG and         psugar synty).         0.3, 6, 12 and 24 monts         Performation           2-Control Group         alleges from antenatal         Ladobaceliu harmous GG and         psugar synty).         25 participants         25 participants           Placebo) (n=471):         chinics         C705, Bifdobaceliu harmous GG and         psugar synty).         27 monts         25 participants           Placebo (n=47):         chinics so terman LS         prodon clinics so terman LS         prodon clinics         2 participants           Placebo (n=47):         chinibaby major neteric terman LS         psugar synty).</th><td></td><td></td><td></td><td></td><td>DSM 24731 strain.</td><td></td><td></td><td></td><td></td></t<>	RCT         039 program women         Industrion criteria         Intervention (1-468):         0.3 g CGS (bovine origin)         Timing of measurements:         Net reported. but 339           1-Response Group         -Pegnant women with         Reeevied capsules containing         was given in placebo         3, 6, 12 and 24 monts         Perpanst womelsed           (Synbiotic) (n=471):         children at high risk of         a pegnant mixture of 36 weeks         (microcrystaline cellubes         3, 6, 12 and 24 monts         Perpanst montsed           2-Control Group         alleges from antenatal         Ladobaceliu harmous GG and         psugar synty).         0.3, 6, 12 and 24 monts         Perpanst montsed           2-Control Group         alleges from antenatal         Ladobaceliu harmous GG and         psugar synty).         0.3, 6, 12 and 24 monts         Performation           2-Control Group         alleges from antenatal         Ladobaceliu harmous GG and         psugar synty).         25 participants         25 participants           Placebo) (n=471):         chinics         C705, Bifdobaceliu harmous GG and         psugar synty).         27 monts         25 participants           Placebo (n=47):         chinics so terman LS         prodon clinics so terman LS         prodon clinics         2 participants           Placebo (n=47):         chinibaby major neteric terman LS         psugar synty).					DSM 24731 strain.				
1-Response Group       -Pregnant women with (Synbotic) (n=468):       Received capsules containing (synbotic) (n=468):       was given in placebo       3.6.1.2 and 24 months       participants completed (price or high risk of allegies from antenatal       Lackobadilus frammosus GG and (microsystaline cellubse       was given in placebo       3.6.1.2 and 24 months       participants         2-Control Group       allegies from antenatal       Lackobadilus frammosus GG and (microsystaline cellubse       (microsystaline cellubse       14e 6-month folow-up and (microsystaline cellubse)       25 participants         2-Control Group       Index at high risk of (placebo) (n=471);       Cros. Bifdobacterium breve       25 participants       25 participants         2-Control Group       Index at high risk of (placebo) (n=471);       Cros. Bifdobacterium breve       10 s sugar syrup).       25 participants         2-Sourcel Group       Received capsules       Indemeticili sis planmosus GG and (s-37 weeks gestational age, twin buby major malformation       8-9 x 10.5 CFU in each capsule.       2-year follow-up (s-37 weeks gestational age, twin buby major malformation       2-year follow-up (s-68)       2-year follow-up (s-68)         2-Sourcel Group       Received capsule.       Received capsule.       Received capsule.       2-year follow-up (s-68)       2-year follow-up (s-68)         2-Sourcel Group       Received capsule.       Received capsule.       Received capsule.       2-year follow-up (s-68)	1-Resonae Group      Pregnant women with (Synbiotic) (n=463);      Pregnant women with (Synbiotic) (n=463);       Reacived capsules containing       was given in placebo       3, 6, 12 and 24 months       participants completed         (Synbiotic) (n=463);       allegies from antenatal       a pregnant mixture of 36 weeks       (microcrystalline cellulose)       3, 6, 12 and 24 months       participants         2-Control Group       allegies from antenatal       Lactobadilus frammosus GG and (picrocystalline cellulose)       Usus sugar synup).       295 participants         7-Strate Machine       Readualine relational age, trainics       Lactobadilus frammosus GG and pus sugar synup).       Usus sugar synup).       25-participants         7-Strate Machine       Readualine relational age, trainics       Lactobadilus frammosus GG and pus sugar synup).       Usus sugar synup).       25-participants         7-Strate Machine       Readualine relational age, trainics       Readualine relational.       Readualine relational.       25-part follow-up         7-Strate Machine       Readualine relational age, trainics       Readualine relational.       Readualine relational.       27-part follow-up         7-Strate Machine       Readualine relational.       Readualine relational.       29-participants       2-part follow-up         7-Strate Machine       Readualine relational.       Readualine relatinin       2-9-part follow-up       2-9	Kukkonen, 2008,	RCT	939 pregnant women	Inclusion criteria	Intervention (n=468):	0.8 g GOS (bovine origin)	Timing of measurements:	Not reported, but 939	Primary outcomes: neonatal morbidity,
children at high risk of     a pregnant mixture of 36 weeks     (microcrystalline collubee     the 6-month follow-up and       allergies from antenatal     Lactobacillus rharmosus GG and     plus sugar syrup).     925 participants       clinics     C705, Brifidobacterium breve     925 participants     925 participants       clinics     C705, Brifidobacterium breve     925 participants     925 participants       clinics     C705, Brifidobacterium breve     925 participants     925 participants       clinics     C705, Brifidobacterium     925 participants     925 participants       clinics     C705, Brifidobacterium     925 participants     925 participants       clinics     C705, Brifidobacterium     926 participants     925 participants       clinics     C705, Brifidobacterium     Excusion Criteria     925 participants       clinics     Laudobacillis reprosibilis representation     84     92       clinics     Rountis after brith, babies     2-year follow-up     2-year follow-up       were given 1 open capsule of the     same probiotics and 0.8 gof     GOS in liquid form daly.     4 weeks before brith and       denotis after brith.     4 weeks before brith and     baby only or predominantly     baby only or predominantly	children at high risk of     a pregnant mixture of 36 weeks     (microcrystalline cellubee     the 6-month follow-up and       allergies from antenatal     Lactobacillus rharmosus GG and     plus sugar syrup).     925 participants       clinics     C705, Brifidobacterium breve     925 participants     925 participants       clinics     C705, Brifidobacterium breve     925 participants     925 participants       clinics     C705, Brifidobacterium     925 participants     925 participants       clinics     C705, Brifidobacterium     925 participants     925 participants       clinics     C705, Brifidobacterium     925 participants     925 participants       clinics     C705, Brifidobacterium     5     926 participants     925 participants       clinics     C705, Brifidobacterium     Exclusion Criteria     925 participants     925 participants       clinics     Labe9a and Propiobibacterium     Exclusion Criteria     1     92 participants       construction     (B-9 x 10 9, CFU in each capsule)     For 6 months after birth, Labies     2     92 participants       were given 1 open capsule of the     same probiotics and 0.8 gof     GOS in liquid form daly.     4     4       form tafter birth.     4 weeks before birth and     6     5     5     5	Helsinki, Finland		1-Response Group	-Pregnant women with	Received capsules containing	was given in placebo	3, 6, 12 and 24 months	participants completed	infantile colic and defecation,
allergies from antenatal Lactobacillus framosus GG and plus sugar syrup). 925 participants clinics C705. Bifiobacterium breve clinics C705. Bifiobacterium breve clinics C705. Bifiobacterium breve C37 weeks gestational age, treudenteichi sep shermani US twin baby, major malformation (8 + x 10 stread) clinicas shermani US twin baby, major malformation (8 + x 10 stread) clinicas capaule). For 6 months after birth, babies were given 1 open capaule of the same probiotics and 0 8 of GOS in liquid from daly. GOS in liquid from daly. 6 months after birth and 6 months after	allergies from antenatal Lactobacillus framosus GG and plus sugar syrup). 925 participants clinics C755. Bifridobacterium breve clinics C755. Bifridobacterium breve clinics C755. Bifridobacterium C37 weeks gestational age, treudenteichi sep shermani US twin baby, major malkomation (8 × 10 s, CFU in aean capsule). For 6 months after birth, babies were given 1 open capsule of the same probiotism and 0.8 of GOS in liquid from daly. GOS in liquid from daly. 6 months after birth. babies the same probiotism and 0.8 of GOS in flored from the same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same probiotism and 0.8 of GOS in flored from table. The same problem table from			(Synbiotic) (n=468):	children at high risk of	a pregnant mixture of 36 weeks	(microcrystalline cellulose		the 6-month follow-up and	nutritional behaviors (vomiting,
clinics         C705, Britdobacterium breve         completed the           Exdusion Criteria         LBb99 and Propioblbacterium         completed the           -37 weeks gestational age, twin baby, major malformation         (39 × 10 °, CFU in each capsule).         2-year follow-up           For 6 months         (8-9 × 10 °, CFU in each capsule).         (8-9 × 10 °, CFU in each capsule).         2-year follow-up           For 6 months after birth, babies         were given 1 open capsule of the         2-year follow-up         2-year follow-up           For 6 months after birth, babies         GOS in liquid form daly.         4 weeks before of the         2-year follow-up           A weeks before birth and         GOS in liquid form daly.         4 weeks before birth and         5 months after birth	clinics         C705, Britdobacterium breve         completed the           Exdusion Criteria         LBb99 and Propioblbacterium         2-year follow-up           -37 weeks gestational age, twin baby, major matkomation         Reudemeichi sep shemani JS         2-year follow-up           For 6 months after birth, babies         Reveloped shematicity, babies         2-year follow-up           were given 1 open capsule of the same probiotics and 0.8 of OSI in liquid form daly.         0.8 of form that for birth, babies         2-year follow-up           A weeks before birth and GOSI in liquid form daly.         4 weeks before birth and 6 months after birth.         2 baby only or predominantly			2-Control Group	allergies from antenatal	Lactobacillus rhamnosus GG and	plus sugar syrup).		925 participants	constipation, excessive crying and
LBb99 and Propiobibacterium 2-year follow-up freudemeichii ssp shemanii JS (8-9 x 10 9, CFU in each capsule). For 6 months after birth, babies were given 1 open capsule of the same probiotics and 0.8 of GOS in liquid form daly. 4 weeks before birth and 6 months after birth. baby only or predominantly	LBb99 and Propiobibacterium 2-year follow-up freudemeichii ssp shemanii JS (8-9 x 10 9, CFU in each capsule). For 6 months after birth, babies were given 1 open capsule of the same probiotics and 0.8 of GOS in liquid form daily. 4 weeks before birth and 6 months after birth. babies before birth and 6 months after birth. babies before birth and 6 months after birth.			(Placebo) (n=471):	clinics	C705, Bifidobacterium breve			completed the	abdominal discomfort)
freudemetchil sep shermanil JS (8-9 x 10 9, CFU in each capsule). For 6 months after birth, babies were given 1 open capsule of the same problotics and 0.8 g of GOS in liquid form daly. 4 weeks before birth and 6 months after birth. baby only or predominantly	freudemetchil sep shermanil JS (8-9 x 10 9. CFU in each capsule). For 6 months after birth, babies were given 1 open capsule of the same probiotics and 0.8 g of GOS in liquid form daly. 4 weeks before birth and 6 months after birth. baby only or predominantly				Exclusion Criteria	LBb99 and Propiobibacterium			2-year follow-up	Secondary outcomes:
<ul> <li>(8-9 x 10 9, CFU in each capsule).</li> <li>For 6 months after birth, babies were given 1 open capsule of the same problotics and 0.8 g of GOS in liquid form daily.</li> <li>4 weeks before birth and 6 months after birth.</li> </ul>	<ul> <li>(8-9 x 10 9, CFU in each capsule).</li> <li>For 6 months after birth, babies were given 1 open capsule of the same probiolics and 0.8 g of GOS in liquid form daily.</li> <li>4 weeks before birth and 6 months after birth.</li> </ul>				<37 weeks gestational age,	freudenreichii ssp shermanii JS				anthropometric measurement,
uables le of the J of baby only or predominantly	uables lie of the g of baby only or predominantly				twin baby, major malformation	(8-9 x 10 9, CFU in each capsule).				infection,
le of the J of	le of the J of					For 6 months after birth, babies				antibiotics and other diseases.
e of	t of					were given 1 open capsule of the				
						same probiotics and 0.8 g of				
						GOS in liquid form daily.				
						4 weeks before birth and				
						6 months after birth.			baby only or predominantly	




FIGURE 2: A) Forest plot of comparison: 1 Probiotic preparation versus placebo, outcome: 1.1 effect of infantile colic on treatment success at the end of the intervention: random-effects model. B) Forest comparison chart: Placebo versus probiotic preparation, effect of infantile colic on treatment success at the end of 1.2 interventions: sensitivity analysis with fixed effect model.

analysis of three studies with 1,097 participants and we did not find a significant difference in terms of treatment success between the two groups (Figure 2A).<sup>26-29</sup> In a sensitivity analysis using the fixed effect model, we found a significant difference in favor of probiotics (Figure 2B).<sup>26</sup> This inconsistency between the two models suggests statistical heterogeneity, and is consistent with the  $I^2$  statistic, which was high at 72%. The quality of the evidence in function was downgraded to moderate quality due to inconsistency.

#### Secondary Outcomes

#### Duration of crying at the end of intervention

The combined results of an RCT reported that the application of the probiotic compared to placebo reduced the crying time at the end of the intervention.<sup>26</sup> However, there was no notification of crying time. There was no significant difference in daily crying time between the placebo group at the end of the intervention, but compared with a RCT, a synbiotic application including *L. rhamnosus LC705, B. breve* 

*Bb99 and P. freudenreichii* ssp *shermanii JS* did not significantly decrease the crying time.<sup>26</sup>

According to these results, four articles reported results about reduced crying time, but they did not report in minutes. We conducted a random-effects metaanalysis of one study with 13 participants, and found a difference between the two groups in favour of prebiotics for crying time (Figure 3A).<sup>28</sup> In a sensitivity analysis using the fixed effect model, we didn't find a significant difference in favor of probiotics (Figure 3B). The quality of the evidence in function was downgraded to low quality due to imprecision and indirectness. In a single RCT, one interventional study, researchers measured the intervention effect and crying time based on parent reports using a validated Barr Diary (a Baby Day Diary) and a stopwatch for timing infant behavior patterns.<sup>28,29</sup> Another 1 RCT was measured using the structured diary and Bristol Stool Form Scale for gastrointestinal events to evaluate the crying times and the daily state of the baby, based on parent reports.<sup>26</sup> In a single RCT a daily form created by researchers was used.<sup>27</sup> In this study,




FIGURE 3: A) Forest plot of comparison: 1 Probiotic preparation versus placebo, outcome: Crying time: random effects model (minutes/day). B) Forest comparison table: Probiotic preparation versus placebo, outcome: Crying time: sensitivity analysis with fixed effect model.

the intervention effect and crying time were measured based on parental contextten reports.

#### **RISK OF BIAS ASSESSMENT**

The conclusions of our 'bias risk' evaluation for the included studies are summarized in Figure 4 and Figure 5.

**Random sequence generation** Except for an interventional study, five studies defined an adequate method of random allocation of participants to intervention groups, so we graduated these studies at low risk of bias on this field.<sup>26-29</sup>

*Allocation concealment* In the studies of Kukkonen et al. and Iacovou et al.; it did not define or mention the hiding of the allocation, so we considered it as a study with an uncertain bias risk. In other two studies, allocation hiding was identified and considered a low risk of bias.<sup>26,28</sup>

**Blinding** All studies, except the Iacovou et al.'s study (single blind), were double-blind. Three studies were graded with risk of performance bias and detection bias, as they did not describe adequate methods for blinding.<sup>26-28</sup>

**Incomplete outcome data** Three studies were evaluated with a low risk of wear bias because there was similar or very little dropout rates between the control and experimental groups.<sup>26-28</sup> We decided that the work of Iacovou is at risk of uncertain wear, since its design does not have a control group and uses every mother as its own control.

*Selective reporting* The two studies were considered a low risk of selection bias, as they discussed all outcomes, including negative outcomes, and reported them in their protocols.<sup>28,29</sup> Two studies carried a high risk in terms of trial registration and reporting bias.<sup>26,27</sup>

*Other potential sources of bias* As other biases in the study, we have taken into account any involvement of companies supplying or producing the intervention product while conducting the studies or the article, due to the use of a product or intervention in such a vulnerable and risky population. We rated the four studies included in the meta-analysis as having low risk of further bias because they declared that they had no financial relationship with either product support, direct financial support for the business, or no financial relationship with the industry.<sup>26-29</sup>

## DISCUSSION

We present the first systematic review of studies dealing with the effect of probiotics added to maternal nutrition in infantile colic. The purpose of this review




FIGURE 4: Bias risk chart in included trials.

was to summarize available proof on the effectiveness of the probiotic supplement given in the prenatal or postnatal period in infantile colic treatment. We focused on two main outcomes only, these were the success of treatment and the duration of crying time per day, as being clinically important. Both outcomes were assessed at the end of the intervention period.

In the literature, there is no systematic review evaluating the effect of probiotics added to maternal nutrition on infantile colic. The extensive and systematic literature search is one of the strengths of this systematic review. Apart from that, we included only probiotic or prebiotic supplements added to the maternal diet. methodological quality (GRADE) of the included studies was average and low, so we are not sure of the effects of the probiotic supplement on crying time, while it has positive results for treatment success.<sup>25</sup> In this review, 3 RCTs available in the literature were conducted on 1 interventional study. Some of the included studies were limited to the study population as well as probiotic and prebiotic supplements. For example, the effect of the probiotic supplementary used in the study of Baldassarre et al. was mainly studied in breast-fed infants; data on formula-fed infants are restricted and do not encourage formula-fed babies.<sup>27</sup> Moreover, prevalence of infantile colic is similar in breastfed and formula-fed infants. Thus, the generalizability of the findings should not be limited. One important limitation of the included studies was the lack of an objective way to assess the duration of crying in infants. In the interventional study of a single RCT, the researchers measured the intervention effect and crying time




FIGURE 5: Assessment of risk of bias

based on parent reports, using a validated Barr Diary (a Baby Day Diary) and a stopwatch for timing infant behavior patterns.<sup>28,29</sup> Another 1 RCT was measured using the structured diary and Bristol Stool Form Scale for gastrointestinal events to evaluate the crying times and the daily state of the baby, based on parent reports.<sup>26</sup> In one RCT, a daily form created by researchers was used. In this study, the intervention effect and crying time were measured based on parental reports, but no clear information about the duration was obtained.<sup>27</sup>

The previous systematic reviews were made to evaluate the effects of probiotic applications on crying time in infants with infantile colic when added to infant feeding. These studies did not include maternal nutrition, but our current findings are consistent with the results of previously published reviews.<sup>30,31</sup> However, the absence of a systematic review focusing only on maternal nutrition causes a situation where the study remains strong but controversial. In addition, as a result of the search criteria valid for the study, very few RCTs were reached, which included only mothers. Apart from that, compared to the probiotics available in the literature, this review included both probiotics and prebiotics.<sup>24,32</sup> Therefore, our analysis defines looking at the role of probiotics and prebiotics in infantile colic treatment according to different treatment options. Anabrees et al. focused on interventions in nursing babies and concluded that probiotics, especially Lactobacillus reuteri, seem to be effective in reducing colic, although there are limitations in these findings.<sup>33</sup> In the study of Dryl and Szajewska, which included seven RCTs (471 participants), the application of L. reuteri DSM 17938 was associated with less cure time at the end of the treatment compared to placebo; however, the effect was found to be mainly in infants who were breastfed only.34

## CONCLUSION

In conclusion, this systematic review confirms that the application of probiotics or prebiotics added to maternal nutrition may be beneficial in infants with infantile colic. Further studies are needed, especially for probiotics and prebiotic supplements added to maternal nutrition. Studies evaluating the effectiveness of some probiotics and/or prebiotics are needed because some preliminary results are quite promising.

#### Source of Finance

During this study, no financial or spiritual support was received neither from any pharmaceutical company that has a direct connection with the research subject, nor from a company that provides or produces medical instruments and materials which may negatively affect the evaluation process of this study.

#### **Conflict of Interest**

No conflicts of interest between the authors and / or family members of the scientific and medical committee members or members of the potential conflicts of interest, counseling, expertise, working conditions, share holding and similar situations in any firm.

#### Authorship Contributions

Idea/Concept: Aysun Yıldız Karaahmet, Gülümser Dolgun, Metehan Özen; Design: Aysun Yıldız Karaahmet, Gülümser Dolgun, Metehan Özen; Control/Supervision: Gülümser Dolgun, Metehan Özen; Data Collection and/or Processing: Aysun Yıldız Karaahmet, Gülümser Dolgun; Analysis and/or Interpretation: Aysun Yıldız Karaahmet, Gülümser Dolgun, Metehan Özen; Literature Review: Aysun Yıldız Karaahmet, Gülümser Dolgun; Writing the Article: Aysun Yıldız Karaahmet, Gülümser Dolgun; Critical Review: ysun Yıldız Karaahmet, Gülümser Dolgun, Metehan Özen.

- B, Harris GS ninga M, Chouraqui JP, Çokura I
- Wessel MA, Cobb JC, Jackson EB, Harris GS Jr, Detwiler AC. Paroxysmal fussing in infancy, sometimes called colic. Pediatrics. 1954;14(5): 421-35. [Pubmed]
- Bennett WE Jr. Probiotics and infant colic. BMJ. 2014;348:g2286. [Crossref] [Pubmed]
- Hyman PE, Milla PJ, Benninga MA, Davidson GP, Fleisher DF, Taminiau J. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2006;130(5):1519-26. [Crossref] [Pubmed]
- Steutel NF, Benninga MA, Langendam MW, de Kruijff I, Tabbers MM. Reporting outcome measures in trials of infant colic. J Pediatr Gastroenterol Nutr. 2014;59(3):341-6. [Crossref] [Pubmed]
- 5. Vandenplas Y, Abkari A, Bellaiche M, Ben-

- ninga M, Chouraqui JP, Çokura F, et al. Prevalence and health outcomes of functional gastrointestinal symptoms in infants from birth to 12 months of age. J Pediatr Gastroenterol Nutr. 2015;61(5):531-7. Erratum in: J Pediatr Gastroenterol Nutr. 2016;62(3):516. [Crossref] [Pubmed] [PMC]
- Drug and Therapeutics Bulletin. Management of infantile colic. BMJ. 2013;347:f4102. [Crossref] [Pubmed]
- Sung V, Collett S, de Gooyer T, Hiscock H, Tang M, Wake M. Probiotics to prevent or treat excessive infant crying: systematic review and meta-analysis. JAMA Pediatr. 2013;167(12): 1150-7. [Crossref] [Pubmed]
- de Weerth C, Fuentes S, Puylaert P, de Vos WM. Intestinal microbiota of infants with colic: development and specific signa-

tures. Pediatrics. 2013;131(2):e550-8. [Crossref] [Pubmed]

- Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-14. [Crossref] [Pubmed]
- Savino F, Cordisco L, Tarasco V, Locatelli E, Di Gioia D, Oggero R, et al. Antagonistic effect of Lactobacillus strains against gas-producing coliforms isolated from colicky infants. BMC Microbiol. 2011;11:157. [Crossref] [Pubmed] [PMC]
- Penna FJ, Péret LA, Vieira LQ, Nicoli JR. Probiotics and mucosal barrier in children. Curr Opin Clin Nutr Metab Care. 2008;11(5):640-4. [Crossref] [Pubmed]

- Liu Y, Fatheree NY, Mangalat N, Rhoads JM. Human-derived probiotic Lactobacillus reuteri strains differentially reduce intestinal inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;299(5):G1087-96. [Crossref] [Pubmed] [PMC]
- Sung V, Hiscock H, Tang M, Mensah FK, Heine RG, Stock A, et al. Probiotics to improve outcomes of colic in the community: protocol for the Baby Biotics randomised controlled trial. BMC Pediatr. 2012;12:135. [Crossref] [Pubmed] [PMC]
- Praveen V, Praveen S, Deshpande G, Patole SK. Oral probiotics for infantile colic. Cochrane Database Syst Rev. 2014;3. [Crossref]
- Savino F, Ceratto S, De Marco A, Cordero di Montezemolo L. Looking for new treatments of Infantile Colic. Ital J Pediatr. 2014; 40:53. [Crossref] [Pubmed] [PMC]
- Sung V, Hiscock H, Tang ML, Mensah FK, Nation ML, Satzke C, et al. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ. 2014;348:g2107. [Crossref] [Pubmed] [PMC]
- Turner TL, Palamountain S (author), Augustyn M (section editor), Torchia MM (deputy editor). Infantile Colic: Management and outcome. Up-ToDate 2014. Cited 5 January 2019. [Link]
- Benninga MA, Faure C, Hyman PE, St James Roberts I, Schechter NL, Nurko S. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2016: S0016-5085(16)00182-7. [Pubmed]
- Talachian E, Bidari A, Rezaie MH. Incidence and risk factors for infantile colic in Iranian infants. World J Gastroenterol. 2008;14(29): 4662-6. [Crossref] [Pubmed] [PMC]
- 20. Savino F, Cordisco L, Tarasco V, Calabrese R, Palumeri E, Matteuzzi D. Molecular identifica-

tion of coliform bacteria from colicky breastfed infants. Acta Paediatr. 2009;98(10):1582-8. [Crossref] [Pubmed]

- Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E, et al. Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One. 2010;5(5):e10667. Erratum in: PLoS One. 2010;5(6). [Crossref] [Pubmed] [PMC]
- Ali AM. Helicobacter pylori and infantile colic. Arch Pediatr Adolesc Med. 2012;166(7):648-50. [Crossref] [Pubmed]
- Newburg DS, Walker WA. Protection of the neonate by the innate immune system of developing gut and of human milk. Pediatr Res. 2007;61(1):2-8. [Crossref] [Pubmed]
- Gutiérrez-Castrellón P, Indrio F, Bolio-Galvis A, Jiménez-Gutiérrez C, Jimenez-Escobar I, López-Velázquez G. Efficacy of Lactobacillus reuteri DSM 17938 for infantile colic: Systematic review with network meta-analysis. Medicine (Baltimore). 2017;96(51):e9375. Erratum in: Medicine (Baltimore). 2018;97(4):e9730. [Crossref] [Pubmed] [PMC]
- Rautava S. Early microbial contact, the breast milk microbiome and child health. J Dev Orig Health Dis. 2016;7(1):5-14. [Crossref] [Pubmed]
- Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebocontrolled trial. Pediatrics. 2008;122(1):8-12. [Crossref] [Pubmed]
- Baldassarre ME, Di Mauro A, Mastromarino P, Fanelli M, Martinelli D, Urbano F, et al. Administration of a multi-strain probiotic product to women in the perinatal period differentially affects the breast milk cytokine profile and

may have beneficial effects on neonatal gastrointestinal functional symptoms. A randomized clinical trial. Nutrients. 2016;8(11):677. [Crossref] [Pubmed] [PMC]

- Iacovou M, Mulcahy EC, Truby H, Barrett JS, Gibson PR, Muir JG. Reducing the maternal dietary intake of indigestible and slowly absorbed short-chain carbohydrates is associated with improved infantile colic: a proof-of-concept study. J Hum Nutr Diet. 2018;31(2):256-65. [Crossref] [Pubmed]
- Iacovou M, Craig SS, Yelland GW, Barrett JS, Gibson PR, Muir JG. Randomised clinical trial: reducing the intake of dietary FODMAPs of breastfeeding mothers is associated with a greater improvement of the symptoms of infantile colic than for a typical diet. Aliment Pharmacol Ther. 2018;48(10):1061-73. [Crossref] [Pubmed]
- Srinivasjois R, Rao S, Patole S. Prebiotic supplementation in preterm neonates: updated systematic review and meta-analysis of randomised controlled trials. Clin Nutr. 2013;32(6):958-65. [Crossref] [Pubmed]
- Aslan NN, Yardımcı H. Anne sütü ve mikrobiyota [Breast milk and microbiota]. Turkiye Klinikleri J Nutr Diet-Special Topics. 2017;3(2):95-100. [Link]
- Rhoads JM. Probiotic Lactobacillus reuteri effective in treating infantile colic and is associated with inflammatory marker reduction. J Pediatr. 2018;196:324-7. [Crossref] [Pubmed]
- Anabrees J, Indrio F, Paes B, AlFaleh K. Probiotics for infantile colic: a systematic review. BMC Pediatr. 2013;13:186. [Crossref] [Pubmed] [PMC]
- Dryl R, Szajewska H. Probiotics for management of infantile colic: a systematic review of randomized controlled trials. Arch Med Sci. 2018;14(5):1137-43. [Crossref] [Pubmed] [PMC]